

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Guangzhou Innogen Pharmaceutical Group Co., Ltd.

廣州銀諾醫藥集團股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2591)

VOLUNTARY ANNOUNCEMENT APPOINTMENT OF SENIOR MANAGEMENT

This announcement is made by Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the **“Company”**, together with its subsidiaries, the **“Group”**) on a voluntary basis. The board (the **“Board”**) of directors (the **“Directors”**) of the Company is pleased to announce that, Mr. Jin Bai (金柏) (**“Mr. Jin”**) has been appointed as the vice president of the Company with effect from 19 October 2026. Mr. Jin will be primarily responsible for the overall commercialisation of the Group's products and other related matters.

The biographical details of Mr. Jin are set out below:

Mr. Jin, aged 46, has over 20 years of experience in pharmaceutical product sales and commercialisation management. Prior to joining the Group, Mr. Jin served as the chief executive officer and chief commercial officer of Beijing Peak Biology Pharmaceuticals Co., Ltd. from January 2025 to October 2026, where he was primarily responsible for the overall business operations and management of the company, team building, market expansion and product-related business collaborations. Mr. Jin spent 19 years of his career at AstraZeneca Investment (China) Co., Ltd. from February 2006 to January 2025, where he successively served as a sales representative, district manager, regional manager, regional sales director, head of cardiovascular business and head of community business, in particular, from October 2023 to January 2025, he served as the head of community business of the omnichannel business unit, and was mainly responsible for managing the unit's sales, marketing, finance and human resources functions.

The Board believes that Mr. Jin's extensive experience in pharmaceutical product sales, commercial operations, team building and systematic management will contribute to the Group's global commercialisation strategy and development.

The Board would like to extend its warm welcome to Mr. Jin on his new appointment.

By order of the Board
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Dr. WANG QINGHUA
Chairman of the Board

Shanghai, the People's Republic of China, 19 October 2026

As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK as non-executive Director; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.